TrialJournal for immunotherapy of cancer2022

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.

Minsuk Kwon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.